

Referral Status:		MRN:	
<input type="checkbox"/> New referral	<input type="checkbox"/> Order change	<input type="checkbox"/> Order Renewal	
Patient preferred clinic:			

Xolair® (omalizumab) Standard Plan of Treatment for Nasal Polyps

PATIENT DEMOGRAPHICS:

Date of Referral:		Patient's Phone:	
Patient Name:		Address:	
Date of Birth:		City, State, Zip:	
Height in inches:	Weight: LB or KG	Gender:	Allergies: <input type="checkbox"/> See list <input type="checkbox"/> NDKA

DIAGNOSIS: (PLEASE COMPLETE 2ND AND 3RD DIGITS TO COMPLETE ICD 10 FOR BILLING)

<input type="checkbox"/> J33.0 Polyp of nasal cavity	<input type="checkbox"/> J33.1 Polypoid sinus degeneration
<input type="checkbox"/> J33.8 Other polyp of sinus	<input type="checkbox"/> J33.9 Nasal polyp
<input type="checkbox"/> - Other:	

REQUESTED DOCUMENTATION: PREVIOUS ADMINISTRATION: HAS THIS PATIENT TAKEN THIS MEDICATION BEFORE?

1	Insurance information	IF NO:	IF YES:
2	Most recent History & Physical	PLEASE STATE	LAST INFUSION DATE:
3	Full medication list	REQUIRED WASHOUT	NEXT INFUSION DATE:
4	Tried and failed therapies	FROM PREVIOUS	IF ORDER CHANGE:
5	Pre-treatment serum IgE level as required for pretreatment dosing	THERAPY:	
			Continue current order until insurance approved

Provider Attestation for HCP administration:

<input type="checkbox"/> Provider attests that the patient or caregiver is not competent or is physically unable to administer the Xolair labeled self-administration.	<input type="checkbox"/> The location and circumstances for self-administration are not adequate for the potential treatment of anaphylaxis should that arise.
<input type="checkbox"/> Patient has experienced severe hypersensitivity reactions to Xolair or other agents, such as foods, drugs, biologics, within the past 6 months or requires administration and direct monitoring by a healthcare professional.	<input type="checkbox"/> Patient has a history of uncontrolled disease and ordering physician attests that in their clinical opinion, it is not advisable to try the self-administration formulation of requested drug
<input type="checkbox"/> Patient has not received at least 3 doses of Xolair under the guidance of a healthcare provider with no hypersensitivity reactions*	<input type="checkbox"/> Due to patient's weight, ordering provider attests that in their clinical opinion, it is not advisable to try the self-administered formulation of requested drug.

*Specific reactions: _____

MEDICATION ORDERS:

NOTE: Patient may be ineligible to receive Xolair® (omalizumab) if patient has signs/symptoms of parasitic infection, is currently being treated for a parasitic infection, or is having acute bronchospasm and/or asthma attack.

MEDICATION/FREQUENCY:

Xolair® (omalizumab) subcutaneously every 2 weeks: Xolair® (omalizumab) subcutaneously every 4 weeks:

DOSE:

75mg/dose 150 mg/dose 225mg/dose 300mg/dose 375mg/dose 450mg/dose
 525mg/dose 600mg/dose

Administer as subcutaneous injection to upper arm, thigh, or abdomen. No more than 150 mg per injection site

SPECIAL ORDERS:

Extended post treatment monitoring for any patient new to therapy: monitor patient for two (2) hours after first injection, for one (1) hour after second injection, for 30-minutes after third injection, and then 15-minutes for all subsequent injections.

Refills x 12 months unless noted otherwise here:

LINE USE/CARE ORDERS: ADVERSE REACTION & ANAPHYLAXIS ORDERS:

Start PIV/Access CVC
 Flush device per facility standard flushing procedure

Administer acute infusion and anaphylaxis medications per Palmetto Infusion standing adverse reaction orders, which can be found at our website or scan here.



PRESCRIBER INFORMATION:

PROVIDER NAME:	PHONE:
ADDRESS:	FAX:
CITY, STATE, ZIP:	NPI:

PRESCRIBER SIGNATURE: (No stamp signatures) DATE

_____	_____
Dispense as written/Brand medically necessary	Substitution permitted



Palmetto

INFUSION

Checklist for referrals to Palmetto Infusion:

Fax referral to 1.866.872.8920

- Patient demographics – address, phone number, SS#, etc.**
- Insurance Information – copy of the card(s) if possible**
- Plan of Treatment/Orders**
- Most recent physician office notes to include tried and failed therapies – all insurance companies that require a pre-authorization require the note. This includes Medicare/Medicaid HMOs.**
- Any lab results or other diagnostic procedures to support the diagnosis**

Palmetto Infusion will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility.

Our office will notify you if any further information is required.

We will review financial responsibility with the patient and refer them to any available co-pay assistance as required. Palmetto Infusion Call Center 800.809.1265. Thank you for the referral.

www.PalmettoInfusion.com